We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
- Authors
Climent, Miguel Ángel; Álvarez, Carlos; Morales, Rafael; Maroto, Pablo; Rodríguez-Vida, Alejo; Méndez-Vidal, María José; del Muro, Xavier García; Puente, Javier; Láinez, Nuria; Vázquez, Sergio; Castellano, Daniel; Lang, Carmen Gómez; Wang, Jing; di Pietro, Alessandra; Davis, Craig; Sanz-Castillo, Belén; Bolós, M. Victoria; Valderrama, Begoña P.
- Abstract
Purpose: Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for overall survival (OS), and additional analyses of survival per a different PD-L1 expression cutoff of ≥ 1% in tumor cells or immune cells (TC/IC). Methods: JAVELIN Bladder 100 data were used for the analysis of the interaction by PD-L1 status (per cutoff used in the trial) for OS and, additionally, OS and progression-free survival (PFS) analyses per a different ≥ 1% TC/IC PD-L1 expression cutoff (Ventana SP263 assay). Results: No significant interaction between treatment and PD-L1 status was observed for OS. Clinically meaningful and robust survival data were observed in favor of avelumab using the different ≥ 1% TC/IC PD-L1 expression cutoff. Conclusions: These results demonstrate the benefit of avelumab maintenance in la/mUC regardless of PD-L1 expression, consistent with approved labels.
- Publication
Clinical & Translational Oncology, 2024, Vol 26, Issue 6, p1532
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-023-03358-4